financetom
Business
financetom
/
Business
/
SRx Health Solutions to Acquire Royal Uranium's Assets
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
SRx Health Solutions to Acquire Royal Uranium's Assets
Aug 18, 2025 5:00 AM

07:34 AM EDT, 08/18/2025 (MT Newswires) -- SRx Health Solutions ( SRXH ) said Monday that it has signed a non-binding agreement to acquire all assets of Royal Uranium, a uranium royalty firm with interests in Canada, Colombia, Argentina, and Namibia.

The company said the deal is subject to final agreements and standard closing conditions.

After the acquisition, SRx Health said it plans to change its name and ticker symbol to reflect a new focus on energy royalties, especially in uranium, a key resource for meeting growing power demands from AI and data centers.

The deal includes 18 uranium royalty assets tied to major development projects in the Americas, SRx Health said.

Shares of the company fell more than 11% in recent premarket activity Monday.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
--Broadcom Guides For FY 2024 Revenue of About $51 Billion, vs CIQ Analyst Consensus of $50.3 Billion
--Broadcom Guides For FY 2024 Revenue of About $51 Billion, vs CIQ Analyst Consensus of $50.3 Billion
Jun 12, 2024
04:17 PM EDT, 06/12/2024 (MT Newswires) -- Price: 1,629.99, Change: +134.48, Percent Change: +8.99 ...
Dave & Buster's Stock Falls On Worse-Than-Expected Q1 Results: The Details
Dave & Buster's Stock Falls On Worse-Than-Expected Q1 Results: The Details
Jun 12, 2024
Dave & Buster’s Entertainment Inc. shares are falling after the company reported its first-quarter financial results Wednesday. Here's a look at the key figures from the report.  The Details: Dave & Buster’s reported quarterly earnings of $1.12 per share which missed the analyst consensus estimate of $1.70 by 34.12% and represented a 22.76% decrease from earnings of $1.45 per share...
Cara Therapeutics discontinues study on a neurological condition as drug fails
Cara Therapeutics discontinues study on a neurological condition as drug fails
Jun 12, 2024
June 12 (Reuters) - Cara Therapeutics ( CARA ) said on Wednesday it will discontinue a mid-to-late stage study for a neurological condition that causes itching after its experimental drug did not demonstrate a meaningful clinical benefit compared to placebo. ...
Chipmaker Broadcom raises annual revenue forecast
Chipmaker Broadcom raises annual revenue forecast
Jun 12, 2024
June 12 (Reuters) - Tech conglomerate Broadcom ( AVGO ) raised its annual revenue forecast on Wednesday, betting on higher demand for its networking equipment and custom chips from businesses investing in artificial intelligence infrastructure. The company expects full-year revenue of about $51 billion, including contribution from VMware, compared with its prior forecast of about $50 billion. Analysts on average...
Copyright 2023-2026 - www.financetom.com All Rights Reserved